Conference Posters

Fatty Acid Receptors GPR40/GPR84: Two Promising Targets in Kidney Fibrosis

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

Activation of the Free-fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease Via a Novel EPO-Independent Mechanism of

PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury

PBI-4050 exerts anti-inflammatory and anti-fibrotic effects in several diabetic and non-diabetic models of kidney injury through modulation of GPR40 and GPR84 fatty acid receptors.

Activation of the Free-Fatty Acid Receptor GPR40 Improves Anemia in Mouse Models of Kidney Disease via a Novel EPO-Independent Mechanism of

The prevalence of anemia increases with the progression of chronic kidney disease (CKD), and leads to reduced quality of life and increased cardiovascular risk.

PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

The aim of this study was to further examine the effects of PBI-4050 in both WT and GPR40 activation-/- mice on adenine-induced tubulointerstitial injury, anemia and the unfolded protein response path

PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice

PBI-4547 administration in prediabetic type 1 NOD mice significantly prevented the evolution to severe diabetes resulting in increased survival.

PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metaboli

Taken together, these results suggest that PBI-4547 offers the potential as a novel therapy for Non-alcoholic fatty liver disease (NAFLD), obesity, type 2 diabetes mellitus, and associated metabolic s

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases and related diabetic nephropathy.

PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism

PBI-4547 reduces Blood glucose, cholesterol and triglycerides levels, Pro-inflammatory and pro-fibrotic markers in liver, Adipocyte size and fibrosis in WAT